LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
October 24, 2023 06:59 ET
|
LianBio
LianBio to receive total upfront consideration of $350 millionLianBio Board of Directors to conduct strategic review of business SHANGHAI and PRINCETON, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) --...
联拓生物与百时美施贵宝就Mavacamten在中国和其它亚洲市场权益达成协议
October 24, 2023 06:59 ET
|
LianBio
上海和新泽西普林斯顿, Oct. 24, 2023 (GLOBE NEWSWIRE) --...
联拓生物宣布Mavacamten （玛伐凯泰）的EXPLORER-CN III期临床研究结果在欧洲心脏病学会年会上公布并同步发表于《JAMA Cardiology》
August 28, 2023 16:05 ET
|
LianBio
EXPLORER-CN研究数据在欧洲心脏病学会年会（ESC）Late-Breaking专场上以口头报告方式公布试验数据同步发表于《JAMA Cardiology》Mavacamten（玛伐凯泰）在中国梗阻性肥厚型心肌病（oHCM）患者的Valsalva 左心室流出道峰值压差、左心室流出道梗阻、临床症状、健康状况、心脏生物标志物和心脏结构等方面均显示出改善研究证实，先前确定的...
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology
August 28, 2023 16:05 ET
|
LianBio
EXPLORER-CN data presented in oral late-breaking science session at ESC 2023Data from the trial published simultaneously in JAMA CardiologyMavacamten demonstrated improvement in Valsalva LVOT peak...
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:05 ET
|
LianBio
Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic...
联拓生物发布2023年第二季度财务业绩数据及公司近期经营动态
August 14, 2023 16:05 ET
|
LianBio
中国国家药品监督管理局（NMPA）正在对mavacamten的新药上市申请（NDA）进行优先审评Mavacamten在中国有症状的梗阻性肥厚型心肌病（oHCM）患者中开展的EXPLORER-CN...
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
August 03, 2023 16:05 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major...
联拓生物宣布SHP2抑制剂BBP-398联合奥希替尼治疗EGFR突变阳性非小细胞肺癌患者的I期临床试验已完成首例患者给药
August 03, 2023 16:05 ET
|
LianBio
上海和新泽西州普林斯顿, Aug. 04, 2023 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克:LIAN)，一家致力于为中国和其他亚洲主要市场的患者带来创新药物的生物技术公司，于今日宣布，评估公司旗下SHP2抑制剂BBP-398联合阿斯利康公司的奥希替尼治疗EGFR突变阳性非小细胞肺癌（NSCLC）患者的I期临床试验已完成首例患者给药。 ...
联拓生物合作伙伴Tarsus Pharmaceuticals宣布美国FDA已批准XDEMVY™ （0.25% 洛替拉纳滴眼液）用于蠕形螨睑缘炎的治疗
July 26, 2023 08:30 ET
|
LianBio
上海和新泽西州普林斯顿, July 26, 2023 (GLOBE NEWSWIRE) -- 联拓生物（纳斯达克股票代码：LIAN）的合作伙伴 Tarsus Pharmaceuticals于昨日宣布，美国食品药品监督管理局（FDA）已批准其产品XDEMVY™ （0.25% 洛替拉纳滴眼液）用于蠕形螨睑缘炎的治疗。XDEMVY（曾用名...
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
July 26, 2023 08:30 ET
|
LianBio
SHANGHAI, China and PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Tarsus Pharmaceuticals (Tarsus), announced yesterday that the U.S. Food and Drug...